Cargando…
The Influence of a Roux-en-Y Gastric Bypass on Plasma Concentrations of Antidepressants
PURPOSE: Roux-en-Y gastric bypass (RYGB) involves alterations of the gastrointestinal tract resulting in altered absorption. Patients with obesity have a higher prevalence of depression, and antidepressants are often prescribed. Alterations caused by RYGB could modify drug bioavailability and cause...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156620/ https://www.ncbi.nlm.nih.gov/pubmed/36949223 http://dx.doi.org/10.1007/s11695-023-06526-1 |
_version_ | 1785036576161529856 |
---|---|
author | Garin, Paul Favre, Lucie Vionnet, Nathalie Frantz, Johanna Eap, Chin B. Vandenberghe, Frederik |
author_facet | Garin, Paul Favre, Lucie Vionnet, Nathalie Frantz, Johanna Eap, Chin B. Vandenberghe, Frederik |
author_sort | Garin, Paul |
collection | PubMed |
description | PURPOSE: Roux-en-Y gastric bypass (RYGB) involves alterations of the gastrointestinal tract resulting in altered absorption. Patients with obesity have a higher prevalence of depression, and antidepressants are often prescribed. Alterations caused by RYGB could modify drug bioavailability and cause potential subtherapeutic plasma concentrations, increasing the risk of depressive relapse. The aim of this study was to describe the evolution of trough drug dose-normalized antidepressant plasma concentrations before and after RYGB. MATERIALS AND METHODS: This naturalistic prospective case series considers patients with trough plasma concentrations in a 1-year timeframe before and after RYGB. Only antidepressants prescribed to at least three patients were included in the present study. RESULTS: Thirteen patients (n = 12 females, median age 44 years, median BMI before intervention = 41.3 kg/m(2)) were included. Two patients were treated concurrently with fluoxetine and trazodone; the remaining patients were all treated with antidepressant monotherapy. Therapeutic drug monitoring (TDM) values for duloxetine (n = 3), escitalopram (n = 4), fluoxetine (n = 4), and trazodone (n = 4) before (median 4.7 weeks) and after (median 21.3 weeks) RYGB intervention were analyzed. Compared to preintervention, median [interquartile range] decreases in dose-normalized trough plasma concentrations for duloxetine (33% [− 47; − 23]), escitalopram (43% [− 51; − 31]), fluoxetine (9% [− 20; 0.2]), and trazodone (16% [− 29; 0.3]) were observed. CONCLUSION: This study shows a decrease in plasma antidepressant concentrations following RYGB. TDM before and after RYGB, in addition to close monitoring of psychiatric symptomatology, may help optimize antidepressant treatment after bariatric surgery. These results also highlight the need for prospective studies assessing the clinical evidence available through TDM in these patients. GRAPHICAL ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-10156620 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-101566202023-05-05 The Influence of a Roux-en-Y Gastric Bypass on Plasma Concentrations of Antidepressants Garin, Paul Favre, Lucie Vionnet, Nathalie Frantz, Johanna Eap, Chin B. Vandenberghe, Frederik Obes Surg Original Contributions PURPOSE: Roux-en-Y gastric bypass (RYGB) involves alterations of the gastrointestinal tract resulting in altered absorption. Patients with obesity have a higher prevalence of depression, and antidepressants are often prescribed. Alterations caused by RYGB could modify drug bioavailability and cause potential subtherapeutic plasma concentrations, increasing the risk of depressive relapse. The aim of this study was to describe the evolution of trough drug dose-normalized antidepressant plasma concentrations before and after RYGB. MATERIALS AND METHODS: This naturalistic prospective case series considers patients with trough plasma concentrations in a 1-year timeframe before and after RYGB. Only antidepressants prescribed to at least three patients were included in the present study. RESULTS: Thirteen patients (n = 12 females, median age 44 years, median BMI before intervention = 41.3 kg/m(2)) were included. Two patients were treated concurrently with fluoxetine and trazodone; the remaining patients were all treated with antidepressant monotherapy. Therapeutic drug monitoring (TDM) values for duloxetine (n = 3), escitalopram (n = 4), fluoxetine (n = 4), and trazodone (n = 4) before (median 4.7 weeks) and after (median 21.3 weeks) RYGB intervention were analyzed. Compared to preintervention, median [interquartile range] decreases in dose-normalized trough plasma concentrations for duloxetine (33% [− 47; − 23]), escitalopram (43% [− 51; − 31]), fluoxetine (9% [− 20; 0.2]), and trazodone (16% [− 29; 0.3]) were observed. CONCLUSION: This study shows a decrease in plasma antidepressant concentrations following RYGB. TDM before and after RYGB, in addition to close monitoring of psychiatric symptomatology, may help optimize antidepressant treatment after bariatric surgery. These results also highlight the need for prospective studies assessing the clinical evidence available through TDM in these patients. GRAPHICAL ABSTRACT: [Image: see text] Springer US 2023-03-22 2023 /pmc/articles/PMC10156620/ /pubmed/36949223 http://dx.doi.org/10.1007/s11695-023-06526-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Contributions Garin, Paul Favre, Lucie Vionnet, Nathalie Frantz, Johanna Eap, Chin B. Vandenberghe, Frederik The Influence of a Roux-en-Y Gastric Bypass on Plasma Concentrations of Antidepressants |
title | The Influence of a Roux-en-Y Gastric Bypass on Plasma Concentrations of Antidepressants |
title_full | The Influence of a Roux-en-Y Gastric Bypass on Plasma Concentrations of Antidepressants |
title_fullStr | The Influence of a Roux-en-Y Gastric Bypass on Plasma Concentrations of Antidepressants |
title_full_unstemmed | The Influence of a Roux-en-Y Gastric Bypass on Plasma Concentrations of Antidepressants |
title_short | The Influence of a Roux-en-Y Gastric Bypass on Plasma Concentrations of Antidepressants |
title_sort | influence of a roux-en-y gastric bypass on plasma concentrations of antidepressants |
topic | Original Contributions |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156620/ https://www.ncbi.nlm.nih.gov/pubmed/36949223 http://dx.doi.org/10.1007/s11695-023-06526-1 |
work_keys_str_mv | AT garinpaul theinfluenceofarouxenygastricbypassonplasmaconcentrationsofantidepressants AT favrelucie theinfluenceofarouxenygastricbypassonplasmaconcentrationsofantidepressants AT vionnetnathalie theinfluenceofarouxenygastricbypassonplasmaconcentrationsofantidepressants AT frantzjohanna theinfluenceofarouxenygastricbypassonplasmaconcentrationsofantidepressants AT eapchinb theinfluenceofarouxenygastricbypassonplasmaconcentrationsofantidepressants AT vandenberghefrederik theinfluenceofarouxenygastricbypassonplasmaconcentrationsofantidepressants AT garinpaul influenceofarouxenygastricbypassonplasmaconcentrationsofantidepressants AT favrelucie influenceofarouxenygastricbypassonplasmaconcentrationsofantidepressants AT vionnetnathalie influenceofarouxenygastricbypassonplasmaconcentrationsofantidepressants AT frantzjohanna influenceofarouxenygastricbypassonplasmaconcentrationsofantidepressants AT eapchinb influenceofarouxenygastricbypassonplasmaconcentrationsofantidepressants AT vandenberghefrederik influenceofarouxenygastricbypassonplasmaconcentrationsofantidepressants |